<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> have been established in athymic, BALB/c mice using the EBV-positive Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line Namalwa </plain></SENT>
<SENT sid="1" pm="."><plain>One-hundred-one of 104 animals (97%) developed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> 10-14 days following s.c. injection of a mixture of 20 x 10(6) Namalwa and 5 X 10(6) irradiated human <z:hpo ids='HP_0100244'>fibrosarcoma</z:hpo> (HT-1080) cells </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> developed at the site of injection and reached approximately 300 mm2 (product of cross-sectional diameters) after 21 days; no <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> were found </plain></SENT>
<SENT sid="3" pm="."><plain>Histological analysis showed that <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> consisted solely of lymphoid cells </plain></SENT>
<SENT sid="4" pm="."><plain>Immunofluorescence assays demonstrated that while 85% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells retained reactivity with the monoclonal B-cell antibody BA-1, 96% retained reactivity with antibody BA-2 and 43% with BA-3 </plain></SENT>
<SENT sid="5" pm="."><plain>A similar reactivity profile was observed with cultured Namalwa cells </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> were passaged serially 10 times without significant change in BA-1, BA-2, or BA-3 reactivity </plain></SENT>
<SENT sid="7" pm="."><plain>Indirect immunofluorescence demonstrated that antibody BA-2 reached <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells within 2 h following i.p. injection; antigen modulation was not observed </plain></SENT>
<SENT sid="8" pm="."><plain>These results demonstrate the suitability of this B-cell model for testing the in vivo efficacy and stability of anti-B-cell immunoconjugates </plain></SENT>
</text></document>